*
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Arcus Biosciences’s 8K filing here.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- What is Forex and How Does it Work?
- California Resources Stock Could Be a Huge Long-Term Winner
- What is a Low P/E Ratio and What Does it Tell Investors?
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Canada Bond Market Holiday: How to Invest and Trade
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
